Life Sciences Real Estate

Analysis of 31 transactions totalling €9 billion reveals investment patterns in European life sciences real estate in €100 million+ price range.

Analysis of 114 transactions totalling €4.4bn reveals investment patterns in European life sciences real estate at €10-100 million price points.

Ten projects from across EMEA have been announced as ULI Europe Awards for Excellence finalists, with life sciences claiming three spots.

France and Ireland lead the €5–10 million bracket, largely concentrated in point of care and R&D assets across Europe.

Converting former science facilities to new uses offers investors portfolio protection against tenant risk while unlocking new income streams.

Life sciences real estate offers institutional investors resilient returns, portfolio diversification, and alignment with healthcare megatrends.